Lam JS - Search Results

1

Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval.

Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ. Klatte T, et al. Among authors: lam js. J Urol. 2007 Jun;177(6):2081-6; discussion 2086-7. doi: 10.1016/j.juro.2007.01.122. J Urol. 2007. PMID: 17509291

2

p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.

Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ. Shvarts O, et al. J Urol. 2005 Mar;173(3):725-8. doi: 10.1097/01.ju.0000152354.08057.2a. J Urol. 2005. PMID: 15711252

3

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Lam JS, et al. J Urol. 2005 Jun;173(6):1853-62. doi: 10.1097/01.ju.0000165693.68449.c3. J Urol. 2005. PMID: 15879764 Review.

4

Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS. Lam JS, et al. Cancer. 2005 Jun 15;103(12):2517-25. doi: 10.1002/cncr.21127. Cancer. 2005. PMID: 15880379 Free article.

5

Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.

Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Lam JS, et al. J Urol. 2005 Aug;174(2):466-72; discussion 472; quiz 801. doi: 10.1097/01.ju.0000165572.38887.da. J Urol. 2005. PMID: 16006866

6

Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.

Leppert JT, Lam JS, Belldegrun AS. Leppert JT, et al. Among authors: lam js. J Immunother. 2005 Sep-Oct;28(5):427-9. doi: 10.1097/01.cji.0000170358.92090.c2. J Immunother. 2005. PMID: 16113598 No abstract available.

7

Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.

Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Lam JS, et al. Urology. 2005 Nov;66(5 Suppl):1-9. doi: 10.1016/j.urology.2005.06.112. Urology. 2005. PMID: 16194700 Review.

8

Long-term outcomes of the surgical management of renal cell carcinoma.

Lam JS, Belldegrun AS, Pantuck AJ. Lam JS, et al. World J Urol. 2006 Aug;24(3):255-66. doi: 10.1007/s00345-006-0055-5. Epub 2006 Feb 15. World J Urol. 2006. PMID: 16479388 Review.

9

Open partial nephrectomy for the treatment of renal cell carcinoma.

Shuch B, Lam JS, Belldegrun AS. Shuch B, et al. Among authors: lam js. Curr Urol Rep. 2006 Jan;7(1):31-8. doi: 10.1007/s11934-006-0035-8. Curr Urol Rep. 2006. PMID: 16480666 Review.

10

Adjuvant treatment for renal cell carcinoma.

Lam JS, Belldegrun AS, Figlin RA. Lam JS, et al. Expert Opin Pharmacother. 2006 Apr;7(6):705-20. doi: 10.1517/14656566.7.6.705. Expert Opin Pharmacother. 2006. PMID: 16556087 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

320 results

Search Page